Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
Healthcare
$19.79 -3.08%
-$0.74 today
- Market cap
- $290.48M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
52W Low $7.78High $34.10
Volume 0.23M
Average 0.14M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$19.45M
FY 2025 · Annual
Net Income
-$19.36M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| Gross Profit | (3.61K) | (3.61K) | (3.61K) | (3.61K) | (1.78K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.56M | 6.48M | 7.7M | 15.48M | 17.22M |
| Selling, General & Admin | 1.04M | 1.56M | 1.63M | 2.15M | 2.23M |
| Operating Expenses | 4.59M | 8.04M | 9.32M | 17.63M | 19.45M |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| EBITDA | (4.57M) | (7.82M) | (8.89M) | (17.41M) | (19.36M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.6M) | (8.04M) | (9.33M) | (17.64M) | (19.45M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 27.37K | 215.02K | 436.06K | 223.01K | 89.7K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 27.37K | 215.02K | 436.06K | 223.01K | 89.7K |
| Income Before Tax | (4.57M) | (7.83M) | (8.89M) | (17.41M) | (19.36M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (4.57M) | (7.83M) | (8.89M) | (17.41M) | (19.36M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.35) | (0.61) | (0.69) | (1.21) | (1.43) |
| EPS (Diluted) | (0.35) | (0.61) | (0.69) | (1.21) | (1.43) |
| 12.94M | 12.91M | 12.85M | 13.01M | 13.53M | |
| 12.94M | 12.91M | 12.85M | 13.01M | 13.53M |
GLSI Earnings Waterfall · TTM
NASDAQ:GLSI · Revenue to Net Income
Key Ratios
EPS$-1.57
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-10.1
P/S Ratio0.0
Analysis
$0 of revenue converted into -$21.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.57, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| DEFA14A | DEFA14A filing | Oct 26, 2026 | |
| DEF 14A | DEF 14A filing | Oct 26, 2026 | |
| ARS | ARS filing | Oct 26, 2026 | |
| 10-Q | Quarterly report | Aug 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 30, 2026 |
How much revenue does GLSI generate?
Greenwich LifeSciences, Inc. (GLSI) reported $0.00 of revenue in fiscal 2025.
Is GLSI profitable?
Greenwich LifeSciences, Inc. (GLSI) reported -$19.36M of net income.
Continue the stock analysis
Jump to another research area for this company.